Results 31 to 40 of about 39,703 (285)

Digoxin and Heart Failure: Are We Clear Yet?

Cardiovascular Innovations and Applications, 2017
The Digoxin Investigation Group trial has multiple flaws in the trial design for the findings to be universally applicable. Digoxin in low serum concentrations (0.5–0.9 ng/mL) has been shown to decrease mortality in heart failure patients.
Amit Gupta, Melissa Dakkak, Alan Miller
doaj   +1 more source

Improving Postdischarge Outcomes in Acute Heart Failure [PDF]

, 2018
The global burden that acute heart failure (AHF) carries has remained unchanged over the past several decades (1). European registries (2–5) showed that 1-year outcome rates remain unacceptably high (Table 1) and confirm that hospitalization for AHF ...
Ambrosy, Andrew P., Antohi, Elena-Laura, Butler, Javed, Chioncel, Ovidiu, Collins, Sean P., Iliescu, Vlad Anton, Maggioni, Aldo P., Mebazaa, Alexandre, Pang, Peter S.   +8 more
core   +1 more source

The effect of different digoxin concentrations on heart tissue and antioxidant status in iron-overloaded rats

ARYA Atherosclerosis, 2018
BACKGROUND: Thalassaemia is a hereditary disorder and has an economic burden on patients and the government. The most prevalent complication in these patients is iron overload which is followed by cardiomyopathy.
Beydolah Shahouzehi, Hamid Reza Nasri, Yaser Masoumi-Ardakani   +2 more
doaj   +1 more source

Junctional Bradycardia as Early Sign of Digoxin Toxicity in a Premature Infant with Congestive Heart Failure due to a Left to Right Shunt

American Journal of Perinatology Reports, 2016
Introduction Congestive heart failure due to left to right cardiac shunt is usually managed medically with diuretics, angiotensin converting enzyme inhibitors, and, in some cases, with the addition of digoxin.
Soham Dasgupta, Ashraf M. Aly, Sunil K. Jain   +2 more
doaj   +1 more source

Population pharmacokinetic analysis and dosage recommendations for digoxin in Japanese patients with atrial fibrillation and heart failure using real-world data

BMC Pharmacology and Toxicology, 2022
Background Digoxin is an important treatment option for reducing the ventricular rate in patients with atrial fibrillation (AF) and heart failure (HF). Digoxin has a narrow therapeutic window and large interindividual variability.
Toshinori Hirai, Hidefumi Kasai, Miyoko Naganuma, Nobuhisa Hagiwara, Tsuyoshi Shiga   +4 more
doaj   +1 more source

Adverse reactions of amiodarone [PDF]

, 2019
Adverse drug reaction is defined by the World Health Organization as any response to a drug that is noxious and unintended and occurs at a dose normally used in man.
Calvosa, Leonardo, Ciacciarelli, Marco, Colunga Biancatelli, Ruben Ml, Congedo, Viviana, Iuliano, Luigi, Polidoro, Alessandro   +5 more
core   +1 more source

Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp. [PDF]

PLoS ONE, 2013
We have reported that the P-gp substrate digoxin required basolateral and apical uptake transport in excess of that allowed by digoxin passive permeability (as measured in the presence of GF120918) to achieve the observed efflux kinetics across MDCK-MDR1-
Annie Albin Lumen, Libin Li, Jiben Li, Zeba Ahmed, Zhou Meng, Albert Owen, Harma Ellens, Ismael J Hidalgo, Joe Bentz   +8 more
doaj   +1 more source

The effect of calcium in water hardness on digoxin plasma levels in an experimental rat model [PDF]

ARYA Atherosclerosis, 2020
BACKGROUND: Digoxin is a drug for ventricular rate control in atrial fibrillation (AF). The major challenge in digoxin therapy is to adjust the appropriate concentration range for this drug due to its narrow therapeutic index.
Shabnam Shahsavand, Mohammad Moshirfar, Seyed Hassan Seyed-Sharifi, Mohammad Amin Younessi-Heravi, Reza Ghasemi, Morteza Valaei, Mohsen Yaghubi   +6 more
doaj   +1 more source

Fatal heart block from intentional yew tree (Taxus baccata) ingestion: a case report [PDF]

, 2019
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org ...
Chan, Mark, G, Natasha, Gorog, Diana, Gue, Ying X.   +3 more
core   +2 more sources

Treatment with Digoxin – is it a clinical challenge? A Retrospective Analysis of Hospitalizations due to Digoxin intoxication

Journal of Education, Health and Sport
Introduction and purpose: Digoxin, a cardiac glycoside derived from Digitalis lanata, has stood as a cornerstone in the treatment of various cardiovascular disorders for centuries.
Marcin Wais, Marlena Zając, Dariusz Gruca, Paweł Zalewski, Wiktor Wróblewski, Adam Raabe, Michał Tchórz   +6 more
doaj   +1 more source